Valneva SE (VALN)
NASDAQ: VALN · IEX Real-Time Price · USD
8.88
+0.07 (0.79%)
At close: May 17, 2024, 4:00 PM
8.85
-0.04 (-0.39%)
After-hours: May 17, 2024, 4:00 PM EDT
Valneva SE Revenue
Valneva SE had revenue of $166.26M in the twelve months ending March 31, 2024, down -58.99% year-over-year. Revenue in the quarter ending March 31, 2024 was $35.60M, a -2.25% decrease year-over-year. In the year 2023, Valneva SE had annual revenue of $170.79M, a decrease of -55.57%.
Revenue (ttm)
$166.26M
Revenue Growth
-58.99%
P/S Ratio
3.64
Revenue / Employee
$245,945
Employees
676
Market Cap
605.68M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 170.79M | -213.57M | -55.57% |
Dec 31, 2022 | 384.36M | -11.19M | -2.83% |
Dec 31, 2021 | 395.55M | 261.01M | 194.01% |
Dec 31, 2020 | 134.54M | -7.26M | -5.12% |
Dec 31, 2019 | 141.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Varex Imaging | 855.80M |
GeneDx Holdings | 221.85M |
SI-BONE | 144.05M |
Harrow Health | 138.68M |
Calliditas Therapeutics AB (publ) | 119.73M |
EyePoint Pharmaceuticals | 50.02M |
VALN News
- 5 days ago - Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine - GlobeNewsWire
- 11 days ago - Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 weeks ago - Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - GlobeNewsWire
- 7 weeks ago - Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F - GlobeNewsWire
- 2 months ago - Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. - GlobeNewsWire
- 2 months ago - French biotech company Valneva raises product sales guidance - Reuters
- 2 months ago - Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook - GlobeNewsWire
- 2 months ago - Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - GlobeNewsWire